Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

Published on May 1, 2019in Nature Medicine30.641
· DOI :10.1038/s41591-019-0424-4
Jordi Rodon23
Estimated H-index: 23
(University of Texas MD Anderson Cancer Center),
Jean-Charles Soria79
Estimated H-index: 79
+ 22 AuthorsRazelle Kurzrock99
Estimated H-index: 99
(UCSD: University of California, San Diego)
Precision medicine focuses on DNA abnormalities, but not all tumors have tractable genomic alterations. The WINTHER trial ( NCT01856296 ) navigated patients to therapy on the basis of fresh biopsy-derived DNA sequencing (arm A; 236 gene panel) or RNA expression (arm B; comparing tumor to normal). The clinical management committee (investigators from five countries) recommended therapies, prioritizing genomic matches; physicians determined the therapy given. Matching scores were calculated post-hoc for each patient, according to drugs received: for DNA, the number of alterations matched divided by the total alteration number; for RNA, expression-matched drug ranks. Overall, 303 patients consented; 107 (35%; 69 in arm A and 38 in arm B) were evaluable for therapy. The median number of previous therapies was three. The most common diagnoses were colon, head and neck, and lung cancers. Among the 107 patients, the rate of stable disease ≥6 months and partial or complete response was 26.2% (arm A: 23.2%; arm B: 31.6% (P = 0.37)). The patient proportion with WINTHER versus previous therapy progression-free survival ratio of >1.5 was 22.4%, which did not meet the pre-specified primary end point. Fewer previous therapies, better performance status and higher matching score correlated with longer progression-free survival (all P < 0.05, multivariate). Our study shows that genomic and transcriptomic profiling are both useful for improving therapy recommendations and patient outcome, and expands personalized cancer treatment.
  • References (39)
  • Citations (14)
📖 Papers frequently viewed together
14 Citations
6 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Cheyennedra C. Bieg-Bourne (SDSU: San Diego State University)H-Index: 1
#2Sherri Z. Millis (Foundation Medicine)H-Index: 11
Last. Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 8 authors...
Enhancements in clinical-grade next-generation sequencing (NGS) have fueled the advancement of precision medicine in the clinical oncology field. Here we survey the molecular profiles of 1,113 patients with diverse malignancies who successfully underwent clinical-grade NGS (236 to 404 genes) in an academic tertiary cancer center. Among the individual tumors examined, the majority showed at least one detectable alteration (97.2%). Amongst 2,045 molecular aberrations was involvement of 302 distinc...
5 CitationsSource
#1Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 9
#2Shumei Kato (UCSD: University of California, San Diego)H-Index: 12
Last. Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 9 authors...
Immunotherapy induces durable responses in a subset of patients with cancer. High TMB may be a response biomarker for PD-1/PD-L1 blockade in tumors such as melanoma and non-small cell lung cancer (NSCLC). Our aim was to examine the relationship between TMB and outcome in diverse cancers treated with various immunotherapies. We reviewed data on 1,638 patients who had undergone comprehensive genomic profiling and had TMB assessment. Immunotherapy-treated patients (N = 151) were analyzed for respon...
302 CitationsSource
#1Shumei Kato (UCSD: University of California, San Diego)H-Index: 12
#2Nithya Krishnamurthy (UCSD: University of California, San Diego)H-Index: 3
Last. Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 10 authors...
Carcinoma of unknown primary (CUP) is a rare and difficult-to-treat malignancy, the management of which might be improved by the identification of actionable driver mutations. We interrogated 54 to 70 genes in 442 patients with CUP using targeted clinical-grade, next-generation sequencing of circulating tumor DNA (ctDNA). Overall, 80% of patients exhibited ctDNA alterations; 66% (290/442) ≥1 characterized alteration(s), excluding variants of unknown significance. TP53 -associated genes were most...
20 CitationsSource
#1Dung T. Le (Johns Hopkins University)H-Index: 23
#2Jennifer N. Durham (Johns Hopkins University)H-Index: 4
Last. Luis A. Diaz (Johns Hopkins University)H-Index: 92
view all 46 authors...
The genomes of cancers deficient in mismatch repair contain exceptionally high numbers of somatic mutations. In a proof-of-concept study, we previously showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death receptor–1 (PD-1). We have now expanded this study to evaluate the efficacy of PD-1 blockade in patients with advanced mismatch repair–deficient cancers across 12 different tumor types. Objective radiogra...
995 CitationsSource
#1Christophe Massard (Université Paris-Saclay)H-Index: 43
#2Stefan Michiels (Université Paris-Saclay)H-Index: 50
Last. Jean-Charles Soria (Université Paris-Saclay)H-Index: 79
view all 33 authors...
130 CitationsSource
#1Apostolia Maria Tsimberidou (University of Texas MD Anderson Cancer Center)H-Index: 50
#2David K. Hong (University of Texas MD Anderson Cancer Center)H-Index: 54
Last. Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 18 authors...
PurposeGenomic profiling is increasingly used in the management of cancer. We have previously reported preliminary results of our precision medicine program. Here, we present response and survival outcomes for 637 additional patients who were referred for phase I trials and were treated with matched targeted therapy (MTT) when available.Patients and MethodsPatients with advanced cancer who underwent tumor genomic analyses were treated with MTT when available.ResultsOverall, 1,179 (82.1%) of 1,43...
17 CitationsSource
#1Maria Schwaederle (UCSD: University of California, San Diego)H-Index: 18
#2Melissa Zhao (UCSD: University of California, San Diego)H-Index: 2
Last. Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 8 authors...
Importance The impact of a biomarker-based (personalized) cancer treatment strategy in the setting of phase 1 clinical trials was analyzed. Objective To compare patient outcomes in phase 1 studies that used a biomarker selection strategy with those that did not. Data Sources PubMed search of phase 1 cancer drug trials (January 1, 2011, through December 31, 2013). Study Selection Studies included trials that evaluated single agents, and reported efficacy end points (at least response rate [RR]). ...
74 CitationsSource
#1Jennifer J. Wheler (University of Texas MD Anderson Cancer Center)H-Index: 32
#2Filip JankuH-Index: 41
Last. Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 19 authors...
Innovative molecular diagnostics deployed in the clinic enable new ways to stratify patients into appropriate treatment regimens. These approaches may resolve a major challenge for early-phase clinical trials, which is to recruit patients who, while having failed previous treatments, may nevertheless respond to molecularly-targeted drugs. We report the findings of a prospective, single-center study conducted in patients with diverse refractory cancers who underwent comprehensive genomic profilin...
71 CitationsSource
#1Maria Schwaederle (UCSD: University of California, San Diego)H-Index: 18
#2Barbara A. Parker (UCSD: University of California, San Diego)H-Index: 52
Last. Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 12 authors...
By profiling their patients' tumors, oncologists now have the option to use molecular results to match patients with drug(s) based on specific biomarkers. In this observational study, 347 patients with solid advanced cancers and next-generation sequencing (NGS) results were evaluated. Outcomes for patients who received a “matched” versus “unmatched” therapy following their NGS results were compared. Eighty-seven patients (25%) were treated with a “matched” therapy, 93 (26.8%) with an “unmatched”...
47 CitationsSource
#1James C. Yao (University of Texas MD Anderson Cancer Center)H-Index: 59
#2Nicola FazioH-Index: 31
Last. Marianne Pavel (Charité)H-Index: 35
view all 22 authors...
Summary Background Effective systemic therapies for patients with advanced, progressive neuroendocrine tumours of the lung or gastrointestinal tract are scarce. We aimed to assess the efficacy and safety of everolimus compared with placebo in this patient population. Methods In the randomised, double-blind, placebo-controlled, phase 3 RADIANT-4 trial, adult patients (aged ≥18 years) with advanced, progressive, well-differentiated, non-functional neuroendocrine tumours of lung or gastrointestinal...
311 CitationsSource
Cited By14
Deep learning has enabled great advances to be made in cancer research with regards to diagnosis, prognosis, and treatment. The study by Wang and colleagues in this issue of Cancer Research develops a deep learning algorithm with the ability to digitally stain histologic images, achieving reliable nuclei segmentation and cell classification. They use this tool to study the tumor morphologic microenvironment in tissue pathology images of patients with lung adenocarcinoma. On the basis of the imag...
#1Rui Chang (CQMU: Chongqing Medical University)H-Index: 1
#2Lin Chen (CQMU: Chongqing Medical University)
Last. Gangxiang Yuan (CQMU: Chongqing Medical University)H-Index: 5
view all 12 authors...
Abstract Combination of corticosteroids (CS) with cyclosporin A (CsA) is widely used in the treatment of autoimmune diseases, autoinflammatory diseases and transplantation rejection. However, some patients fail to respond or develop resistance to the combination regimen. In Vogt-Koyanagi-Harada (VKH) disease model, we performed RNA sequencing (RNA-seq) based transcriptomics, isobaric tags for relative and absolute quantification (iTRAQ) based proteomics and assays in vitro to screen and validate...
#1Subbiah (University of Texas MD Anderson Cancer Center)
#1Vivek Subbiah (University of Texas MD Anderson Cancer Center)H-Index: 25
Last. Filip Janku (University of Texas MD Anderson Cancer Center)H-Index: 41
view all 13 authors...
Background: Angiogenesis and activation of the epidermal growth factor (EGFR) pathway play an essential role in tumor proliferation and metastasis. Targeting angiogenesis or EGFR alone does not yield adequate tumor control in most solid tumors. Overcoming intrinsic and/or acquired resistance may need a doublet or triplet therapy strategy. Herein, we report the safety and feasibility of dual EGFR blockade with EGFR monoclonal antibody and EGFR tyrosine kinase inhibitor combined with anti-VEGF ant...
#2Noelia TarazonaH-Index: 7
Last. Andrés CervantesH-Index: 56
view all 9 authors...
Translational research has revolutionized how we develop new treatments for cancer patients. The change from an organ-centric concept guiding treatment choice towards deep molecular analysis, driving a personalized approach, is one of the most important advances of modern oncology. Several tools such as next generation sequencing and RNA sequencing have greatly improved the capacity to detect predictive and prognostic molecular alterations. Detection of gene mutations, amplifications, and fusion...
#1Valerie Pestinger (University of Birmingham)H-Index: 1
#2Matthew Smith (Queen Elizabeth Hospital Birmingham)H-Index: 5
Last. Andrew D Beggs (University of Birmingham)H-Index: 20
view all 9 authors...
INTRODUCTION: The identification of tumour mutational burden (TMB) as a biomarker of response to programmed cell death protein 1 (PD-1) immunotherapy has necessitated the development of genomic assays to measure this. We carried out comprehensive molecular profiling of cancers using the Illumina TruSight Oncology 500 (TSO500) panel and compared these to whole-genome sequencing (WGS). METHODS: Cancer samples derived from formalin-fixed material were profiled on the TSO500 panel, sequenced on an I...
#1David S.P. Tan (NUS: National University of Singapore)H-Index: 26
#1David Tan (NUS: National University of Singapore)
Last. William Yk Hwang (NUS: National University of Singapore)H-Index: 18
view all 7 authors...
Next-generation sequencing (NGS)-based diagnostics have demonstrated clinical utility in predicting improved survival benefits with targeted treatment in certain cancer types, and positive cost-benefit in several healthcare systems. However, clinical adoption in Singapore remains low despite commercial availability of these diagnostics. This expert opinion review examines the key challenges to the clinical adoption of NGS-based diagnostics in Singapore, provides recommendations on impactful init...
#1Jae Il Joo (KAIST)H-Index: 3
#2Minsoo Choi (KAIST)H-Index: 5
Last. Kwang-Hyun Cho (KAIST)H-Index: 43
view all 7 authors...
Many clinical trials for cancer precision medicine have yielded unsatisfactory results due to challenges such as drug resistance and low efficacy. Drug resistance is often caused by the complex compensatory regulation within the biomolecular network in a cancer cell. Recently, systems biological studies have modeled and simulated such complex networks to unravel the hidden mechanisms of drug resistance and identify promising new drug targets or combinatorial or sequential treatments for overcomi...
Last. Dimitrios H Roukos (Academy of Athens)H-Index: 4
view all 4 authors...
#1Maxim SorokinH-Index: 9
#2Elena Poddubskaya (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 9
Last. Andrew GarazhaH-Index: 10
view all 12 authors...
Gastric cancer (GC) is the fifth cancer type by associated mortality. Proportion of early diagnosis is low, and most patients are diagnosed at the advanced stages. First line therapy standardly includes fluoropyrimidines and platinum compounds with trastuzumab for HER2-positive cases. For the recurrent disease there are several alternative options including ramucirumab, a monoclonal therapeutic antibody that inhibits VEGF-mediated tumor angiogenesis by binding with VEGFR2, alone or in combinatio...
2 CitationsSource